23
Jul 2026
MEK inhibition could limit T cell exhaustion and give a boost to immunotherapy
A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors.
-
Life can be betterWe are developing drug products isolated from plant extracts
with history in traditional medicine. -
Improving healthImproving health and wellbeing of the people
is our ultimate goal at Mercury Pharmaceuticals. -
ENTREPRENEURIAL MINDSETHands-on approach to manage projects with proactivity and flexibility.
Welcome to Mercury Pharmaceuticals
We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
OUR Science
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
- NeuroscienceAmong the global leaders in Neuroscience
- OncologyTreatments for niche cancers.
- Research & Development Building a sustainable R&D pipeline.
- Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
23
Jul 2026
Study reveals high prevalence of post-pandemic fatigue and sleep disturbances
Disrupted sleep and anxiety may be an ongoing issue for many people after the pandemic, whether due to COVID-19 directly or to the stress and anxiety caused by the global pandemic, and may contribute to the fatigue commonly reported by people with Post-COVID-19 Syndrome (PCS, or 'long COVID').
23
Jul 2026
Researchers develop artery-on-a-chip platform to predict stroke risk
Predicting an individual's risk of ischemic stroke is difficult because thrombosis embolization-the process of a blood clot detaching from the area where it formed and traveling to and then sticking in another blood vessel-is based on factors that are unique to each person.
23
Jul 2026
Mass-producible immune cells fight solid human tumors in mice
Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted into mice. The Kobe University development is a significant contribution towards faster and cheaper cancer immunotherapy.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.